Drug Profile
Research programme: antibody therapeutics - Medarex
Alternative Names: MDX-1110; MDX-1204; MDX-1414Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Medarex
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CXCR4 receptor antagonists; Fucosyl GM1 ganglioside inhibitors; Glypican 3 inhibitors; Megakaryocyte potentiating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 02 Sep 2009 Medarex has been acquired by Bristol-Myers Squibb
- 27 May 2009 The US FDA approves IND application for MDX-1338 in Acute myeloid leukaemia